Tracking safety of oral semaglutide for type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tracks the safety and effectiveness of Rybelsus (oral semaglutide) in people with type 2 diabetes who are starting the medication as part of their usual care. It helps confirm that the drug works well and is safe in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years of age or older.
- You have type 2 diabetes and your doctor has decided to start you on Rybelsus (oral semaglutide) as part of your regular care.
- You have not taken Rybelsus before.
- If you are a woman who can have children, you are not pregnant, not breastfeeding, and are using effective birth control.
- You do not have a personal or family history of a rare thyroid cancer (medullary thyroid carcinoma) or a condition called MEN2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This study tests a new medication called semaglutide (similar to Ozempic) in people with type 2 diabetes who are already taking metformin. It aims to see if this medication improves blood sugar control and may also help with weight loss.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.